source
- Pressure piles on Amgen after EU pulls Tavneos, flags 'serious breaches' in pivotal studySponsors of the pivotal study behind Amgen’s rare disease drug Tavneos saw unblinded findings for the drug and re-adjudicated data from nine patients to make the drug seem effective, according to E…BioSpace · 1h ago↗ source
- Bankrupt Sangamo sells Fabry gene therapy to PTC and prion program to Lilly for $161MSangamo Therapeutics, currently in Chapter 11 bankruptcy, has agreed to divest its Fabry disease gene therapy and several other platforms to raise cash for the restructuring. PTC Therapeutics emer…